NCT04155749: Phase 1 : CART-ddBCMA - Master Protocol for Cell Therapies in Multiple Myeloma
NCT03941860: Phase 3 - EAA171 - OPTIMUM - Addition of Ixazomib to Lenalidomide in Residual Myeloma
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT03617731: Phase 3 - Effect of Isatuximab to RVd Induction and Len Maintenance in NDMM (GMMG HD7)
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
NCT03720041: Phase 3 Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Elig. New MM (FiTNEss)
NCT03289299 : Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
NCT03224507: Phase 2 - Monoclonal Antibody-Based Sequential Therapy for Deep Remission in MM -MASTER
NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN
NCT02659293: Phase 3 - ATLAS Trial: Carfilzomib, Lenalidomide & Dex Vs Lenalidomide Alone After ASCT
NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study